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Prospective Randomized Trial of Tacrolimus and Prednisone Versus 
Tacrolimus, Prednisone, and Mycophenolate Mofetil: Complete Report 
on 350 Primary Adult Liver Transplantations 
A. Jain, R. Kashyap, D. Kramer, F. Dodson, I. Hamad, T.E. Starzl, and J.J. Fung 
TACROLlMUS (Tac) was approved by the FDA for 
clinical use in liver transplantation in 1993 and .myco-
phenolate mofetil (MMF) was approved in 1995 for use in 
kidney transplantation with cyclosporine. The aim of the 
present study was to compare the combination of Tac and 
steroids (double therapy, group D) versus tacrolimus, ste-
roids, and MMF (triple therapy, group T) in primary adult 
(age> IS years) liver transplantation (LTx). An interim 
report was published on the first 200 patients with a mean 
follow-up of 12.7 ::': 0.4 months. l The present report 
includes the entire study population of 350 consenting 
patients enrolled between August 1995 and May 1995. All 
patients were followed until January 2000 with a mean 
follow-up of 33.S ::': 9.1 months (range 20 to 53). Patient and 
donor characteristics were similar in both groups. 
PROTOCOL 
Patients in both arms of the study received Tac at 0.03 to 0.05 
mglkg per day intravenously as a starting dose. All patients also 
received 1 g of methylprednisolone on reperfusion of the liver and 
a 6-day methylprednisolone taper, starting at 200 mg/d and ending 
at a baseline dose of 20 mg/d. Patients randomized to Tac, steroids, 
and MMF (group T) received 1 g of MMF twice a day orally from 
the day of transplant. The protocol allowed reduction or discon-
tinuation of MMF if there were any side effects ascribed to MMF 
or if the clinical course of the patient deemed it necessary. In 
addition, patients randomized to double-drug therapy could re-
ceive MMF to control acute rejection or Tac-related toxicity. Acute 
rejection episodes.were initially treated with steroid bolus. Steroid-
resistant rejections were treated with 5 mg of OKT3. All rejection 
episodes, which required treatment (biopsy proven or clinically 
suspected) were included. 
RESULTS 
There were no differences in Kaplan-Meier patient survival 
and graft survival in the two groups as shown in Table 1. 
One-year actual patient survival was S5.1 % and actuarial 
survival was S1.6%, 78.6%, and 75.S% for 2, 3, and 4 years, 
respectively, for group D, and that for group Twas S7.4%, 
85.4%, S1.3%. and 79.9%. respectively, at the same time-
points. Twenty patients (11.4%) in group D and 21 (12%) in 
group T required retransplantathln. Overall graft survival 
for group D was 77%, 73.4%, 71.2%, and 70% for 1, 2, 3, 
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and 4 years, respectively, and that for group Twas 82.3, 
• 7S.2%, 75.1 %, and 72.1 % for the sume timepoints. 
Crossover 
During the study period, 38 patients (18.3%) who were 
randomized to the two drug regimens received MMF to 
control ongoing rejection (1/ = 23; 13.1 %), nephr~toxicity . 
(n = 5; 2.8%), nephrotoxicity + rejection (n = 5; 2.8%), 
neurotoxicity (n = 3; 1.7%), neurotoxicity + rejection (11 = 
1, 0.6%), and neurotoxicity + nephrotoxicity + rejection 
(11 = 1, 0.6%). Mean time to introduction of MMF was 
46.4 ::': 72.1 (median 17, range 1 to 385) days after LTx. On 
the other hand, 103 patients (5S.9%) in group T discontin-
ued MMF, including 36 (20.5%) for infection, 29 (16.6%) 
for gastrointestinal complications, 31 (17.7%) for hemato-
logic reasons, and 7 (4.0%) for miscellaneous reasons. 
Mean time to discontinuation of the drug was 68.7 ::': 87.7 
(median 34, range 1 to 434) days from the time of trans-
plantation. 
Rate and Treatment of Rejection 
The overall rate of rejection was not significantly different 
between group D (15.2%) and group T (38.9%), at P = .23. 
However, the rate of rejection in the first 3 months was 
significantly lower in group T (2S%) than in group D 
(38.9%), at P = .03. The rate of rejection for group Twas 
higher in the 3- to 12-month interval (23.5%) than in group 
D (11.3%); however, this did not reach statistical signifi-
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Table 1. Study Results 
Survival 
Months Post-LTx 3 6 12 24 36 
Patient survival D 88.6 86.9 8.5.1 81.6 78.6 
T 89.7 89.1 87.4 85.1 81.3 
Graft survival D 81.6 79.3 77.0 73.4 71.2 
T 84.0 83.4 82.3 78.2 75.1 
Rejection 
Months post-LTx <3 >3<12 >12<24 >24 Total 
n(%) (n%) - n(%) n(%) n(%) 
No. of rejection episodes D 107 (61.1)* 98 96 96 96 (54.8)1 
0 T 126 (72%)" 110 108 107 
D 68 (38.9" 9 2 0 79 
T_ 49 (28)' 16 2 68 
2 D 14 10 1 26 
T 18 6 0 25 
3 D 4 5 0 10 
T 1 9 0 0 4 
4 D 2 2 2 0 6 
T 2 2 0 0 4 
Total n (% of total rejection) D 88 (72.2) 26 (21.5) 6 (5.0) 1 (0.8) 121 
T 70 (65.4) 33 (30.8) 3 (2.8) 1 (0.8) 107 
Mean rejection per patient in D MKS9~ 
T 0.61· 
Immunosuppression 
Months post-L Tx 3 6 12 24 
Mean Tacro dose mg/d D 8.6 8.3 7.2 4.9 3.4 
T 8.2 8.3 7.2 5.6 4.6 
Mean Tacro level ng/mL D 12.0 11 10.1 7.1 8.1 
T 11.20 10.3 9.8 8.7 9.2 
Mean Pred dose mg/d D 10.1 7.9 5.6 3.7 2.5 
T 9.1 7.5 5.4 3.5 2.2 
% Difference in pred dose between D and 9.9 5.1 3.6 5.4 12.0 
Patients % off steroid D 1.8 12 20.2 36.9 60.0 
T 1.2 12.7 30.5 47.5 68.6 
Hematology 
Months post-L Tx a 3 6 12 
Leukopenia % 0 29.5 3.8 9.9 18.8 18.1 
(WBC < 4.0 klmL) T 26.8 7.1 17.8 15.3 19.3 
Anemia % 0 10.7 13.7 2.2 1.9 1.2 
(HCT < 25%) T 10.1 14.2 4.2 0.0 1.0 
Thrombocytopenia % D 32.2 7.6 2.2 1.9 2.5 
(Platelets < 50 klmL) T 31.5 2.5 1.4 1.9 2.0 
Renal Function 
Months post-LTx 0 3 6 12 24 
Blood urea nitrogen mg/dl* D 19.7 + 12.8 28 + 15.7 28.3 + 13.8 24.9 + 10.6 25 + 11 
T 18 + 12 25 + 11 26 + 11 24 + 11 24 + 11 
Creatinine mg/dl* D 1.0 + 0.8 1.3 + 0.6 1.3 + 0.6 1.3 + 0.3 1.6 + 1.5 
T 1.1 + 0.9 1.3+0.9 1.4 + 1.1 1.3+0.6 1.6 + 1.4 
D, double group; t, triple group. 
All values are mean:: SO. 
'p = 0.03. 
rp = .23. 
+P = .69. 
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cance (P = .2). The median time to the first episode of 
rejection from liver transplantation was delayed for group T 
(24.0 days) compared with group D (14 days) (P = .08). 
Cumulative episodes of rejection were 121 (0.69/patient) in 
group D versus 108 (0.61/patient) group T. 
Treatment of Rejection 
Seven patients (4%) in group D and three patients (2.8%) 
in group T required antimurine antibody. The remaining 
rejections were treated with 1 g of methylprednisolone (n = 
51 in group D, n = 40 in group T) or 1 g methylpred-
nisolone and 600 mg of steroid taper over the next 5 days 
(/1 = 63 in group D, Il = 63 in group T). Two subjects in 
group T were treated with oral prednisone only. 
Baseline Maintenance Immunosuppression 
The baseline mean maintenance dose of tacrolimus and 
trough tacrolimus concentration were comparable in both 
groups (Fig. 1). Also, mean prednisone dose was 3.6% to 
12% lower in group T at most timepoints. Freedom from 
prednisone was slightly higher in group T (68.6%) at 2 years 
versus group D (60.6%), but his did not reach statistical 
significance. 
Renal Function 
The mean serum creatinine and blood urea nitrogen at the 
time of LTx was 1.0 ::!:: 0.8 and 19.7 ::!:: 12.8 in group D and 
1.1 ::!:: 0.9 and 18 ::!:: 12 in group T, respectively. Subsequent 
changes are shown in Table 1. In group D, 39 patients 
.(22.7%) required dialysis who. were not on dialysis be~ore 
transplantation, and 20 (11.4%) patients in group T re-
quired dialysis who were not on dialysis prior to transplan-
tation. 
Hematology 
At pretransplant, 10.7% of the patients in group D were 
anemic (Hct < 25) before LTx, and 10.1% in group T. 
Leukopenia (total leukocyte count <4000/mL) was ob-
served in 29.5% oC patients in group D and 26.8% of 
patients in group T. Thrombocytopenia wa; detected m 
32.2% in group D and 31.5% in group T (Fig. 1). 
JAIN, KASHYAP, KRAMER ET AL 
DISCUSSION 
Several reports have been published on its use in liver 
transplantation with CsA and tacrolimus as primary treat-
ment for steroid-resistant rejection, steroid-sparing effects, 
or to improve renal function by reducing the dose of 
calcineurin inhibitor and other immunosuppression-related 
complications. Klupp et alc reported a series of 120 cases 
comparing neoral + MMF and tacrolimus + MMF with 
tacrolimus alone. The rate of discontinuation of MMF was 
58%. In multicenter trial' consisting of 565 patients ran-
domized to CsA + steroid + azathioprine (n = 287),-or 
CsA + steroid + MMF (n = 278), the withdrawal rate of 
MMF was 45.3% and that of azathioprine was 44%. Both 
studies found that, after primary LTx, almost half of the 
patients could not be continued on MMF. The rate of 
rejection was significantly lower at 3 months in the group of 
patients randomized to MMF in our protocol; however, this 
rate of rejection increased in the subsequent year as MMF 
was discontinued, and although the overall rate was lower 
the initial significant advantage was lost. The use of MMF 
did have some other advantages, however, including re-
duced renal toxicity. 
In conclusion, no benefit in patient survival or graft 
survival was observed with use of MMF _ Preexisting leuko-
penia and thrombocytopenia contributed to the need for 
discontinuation of MMF)n a large percentage of patients. 
Trends toward lower incidence of rejection, lower rate of 
preioperative renal impairment, and slightly lower steroid 
requirement were observed. MMF may be more suitable for 
selected patients after LTx who have steroid-resistant re-
jection, nephrotoxicity, neurotoxicity, or a need for a ste-
roid-weaning protocol. 
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